Endpoints NewsOriginal article
#ERS26: Beam says AATD base editing data hold up after one year
Data ReadoutpositivePositive
AI Analysis
Summary
Beam Therapeutics presented one-year follow-up data from a Phase 1/2 study of its base editing gene therapy for alpha-1 antitrypsin deficiency, showing the treatment data held up in six patients. The positive interim results from the early-stage trial support continued development of the candidate.
Clinical Trial Data
Phase
1/2
Patients
6
Outcome Details
Base editing data from Phase 1/2 study in AATD hold up after one year in six patients
Importance:6/10
Sentiment:
0.60
gene therapybase editingrare diseaseAATDPhase 1/2lung diseaseliver disease
Related Companies
Read the original article
Published by Endpoints News on September 8, 2026 8:30 AM